Philip Morris International Progresses Towards Smoke-Free Future

Sep.16.2022
Philip Morris International Progresses Towards Smoke-Free Future
PMI aims to end cigarette sales and promote smoke-free alternatives, with decreasing sales and increasing investment in innovation products.

PMI is often asked if it truly intends to end cigarette sales.


The answer is: yes.


Philip Morris International acknowledges that the decline in cigarette sales - or broadly speaking, the decline in the combustible product portfolio of PMI - is a necessary component in achieving its ambitions for a smoke-free future.


Fimo International is rapidly making progress towards this goal.


According to data publicly released by Fumo International, their cigarette sales have been on a downward trend for the past decade.


The annual sales volume of cigarettes has declined from 91.5 billion units in 2011 to 62.5 billion units in 2021, decreasing every year over the past nine years.


Furthermore, PMI has set a target for the total shipment of combustible products to be below 550 billion units by 2025, as stated in their 2021 comprehensive report.


The cigarette shipments of PMI (Phillip Morris International) have decreased from 915 billion in 2011 to 625 billion in 2021.


Phimo International aims to ultimately replace cigarettes with smoke-free alternatives.


Since 2008, Philip Morris International has invested over 9 billion dollars in the research and development, product development, production capabilities, scientific validation, and understanding of adult smokers for these innovative products.


This is a successful investment as an increasing number of adult smokers are switching to FiMO International's heated tobacco products, leading to a reduction in cigarette transportation volume.


As of June 30th, 2022, approximately 13.2 million adult smokers have switched to smoke-free alternatives and quit smoking.


The shipment volume of PhiMo International's heated tobacco devices has increased from 7 billion in 2016 to 95 billion in 2021.


These figures are transparently released annually by Fimo International for anyone to access.


Although the optimal choice for any smoker is to completely quit smoking and nicotine, scientifically proven smokeless products are a better option for adult smokers who would otherwise continue smoking.


According to Moira Gilchrist, VP of Strategic and Scientific Communication at Philip Morris International, the company's decision to unilaterally stop selling cigarettes tomorrow will not change anything. "Because it doesn't eliminate the demand for cigarettes. The demand will remain, and others will simply fill it, whether it be competitors or participants in the black market.


Our transition is more significant because we are striving to reduce the long-term demand for cigarettes, ensuring that the decline in the number of smokers continues - and may even accelerate further.


These numbers cannot be ignored," said Stefano Volpetti, President of the PMI Smoke-Free Products category and Chief Consumer Officer. "They clearly depict the transformation that Philip Morris International is driving - first, providing a range of better alternatives for adult smokers and secondly, accelerating smoking cessation.


Our scientific evidence confirms that PMI's smoke-free products, while not without risk, are a better choice than cigarettes for adults who would otherwise continue to smoke.


With support from the industry, stakeholders, and civil society, we believe that cigarette sales can come to an end in many countries within 10 to 15 years. This would be an enduring achievement for the global population of 1 billion smokers, global public health, and our company.


As of June 30, 2022, Philip Morris International (PMI) estimates that approximately 13.2 million adult individuals worldwide (excluding Russia and Ukraine) have switched to their heated tobacco products and quit smoking. These user statistics are reflective of PMI's estimates, which are based on consumer statements and sample-based statistical evaluations, with an average margin of error of +/-5% within the 95% confidence interval in key quantity markets. The accuracy and reliability of user statistics may vary depending on the maturity of individual markets and the availability of information.


Statement:


The content of this article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The translation of this article is for industry exchange and research purposes only.


Due to the limitations of the translator's skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS’ viewpoints and statements on any domestic, Hong Kong, Macau, Taiwan, or international issues are entirely aligned with those of the Chinese government.


The copyright of compiled information belongs to the original media outlet and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
Gallup Tracks Nicotine Pouch Use for the First Time: 11% of U.S. Adults Smoke, 9% Vape and 4% Use Nicotine Pouches
Gallup Tracks Nicotine Pouch Use for the First Time: 11% of U.S. Adults Smoke, 9% Vape and 4% Use Nicotine Pouches
Gallup’s 2026 Consumption Habits survey tracked nicotine pouch use for the first time. The survey found that 11% of U.S. adults reported smoking cigarettes in the past week, 9% reported vaping, and 4% reported using nicotine pouches. Cigarette smoking remained near Gallup’s long-term low, while adult vaping rates stayed relatively stable in recent years.
Market
Aug.25 by 2Firsts Perspectives
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19